Showing results (31-40 of 125) with videos related to
Sort By:
Pageof 13
The Journal of Pathology|April 30, 2009
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcomaRaffaella De Maria, Silvia Miretti, Selina Iussich, et al.Cancer Research|September 23, 2003
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinaseMartin Sattler, Yuri B Pride, Patrick Ma, et al.Cancer Immunology, Immunotherapy : CII|November 11, 2017
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapyDavid Briere, Niranjan Sudhakar, David M Woods, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PETJeffrey R Tseng, Keon Wook Kang, Mangal Dandekar, et al.Cancer Research|October 19, 2010
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumorsFarbod Shojaei, Joseph H Lee, Brett H Simmons, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitorsPaolo Accornero, Giuseppe Lattanzio, Tony Mangano, et al.Molecular Cancer Therapeutics|November 1, 2008
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cellsThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.Biochemistry|May 23, 2009
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitorsSergei L Timofeevski, Michele A McTigue, Kevin Ryan, et al.Cancer Chemotherapy and Pharmacology|June 12, 2012
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) miceBrett H Simmons, Joseph H Lee, Kush Lalwani, et al.Molecular Cancer Therapeutics|August 15, 2012
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutationSun Mi Kim, Oh-Joon Kwon, Yun Kyoung Hong, et al.Pageof 13